2Anekonda TS,Quinn JF.Calcium channel blocking as a therapeutic strategy for Alzheimer's disease:the case for isradipine[J].Biochim Biophys Acta,2011,1812(12):1584.
3Tsef LS,Jaffe JM.Pharmacokinetics of PN 200-110(isradipine),a new calcium antagonist,after oral administration in man[J].Eur J Clin Pharmacol,1987,32(4):361.
4Bidouil S,Dubois J,Hanocq M.Isocratic high-performance liquid chromatographic method for the separation of isradipine and its main metabolites:application to in vitro metabolization by h3A4/OR cells[J].J Chromatogr B,1997,693(2):359.
5Takamura K,Kusu F,Abdel-Wadood H,et al.Redox properties of isradipine and its electrochemical detection in the HPLC determination of the compound in human serum[J].Biomed Chromatogr,2000,14(7):453.
6Park JH,Park YS,Rhim SY,et al.Quantification of isradipine in human plasma using LC/MS/MS for pharmacokinetic and bioequivalence study[J].J Chromatogr B,2009,877(1):59.
7Christensen HR,Antonsen K,Simonsen K,et al.Bioavailability and Pharmacokinetics of isradipine after oral and intravenous administration:half-life shorter than expected?[J].Pharmacol Toxicol,2000,86(4):178.
8Flynn JT,Pasko DA.Calcium channel blockers:pharmacology and place in therapy of pediatric hypertension[J].Pediatr Nephrol,2000,15(3-4):302.
9Schran HF,Jaffe JM,Gonasun LM.Clinical pharmacokinetics of isradipine[J].Am J Chin Med,1988,84(3):80.
